Stanley Mathew, MD
Endocrinology, Diabetes & Metabolism · Saint Peters, MONPI 1376644484
Payments from drug & device makers
Across 460 payments — averaging $79.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Johnson & Johnson$15K
- Lilly USA, LLC$706
- Novo Nordisk$702
- Amgen$620
- Sanofi-aventis U.S. LLC$497
- plus $4K from 32 others
What the payments were for
- Speaking & faculty fees$27,90076%
- Travel & lodging$730%
- Food & beverage$8,38323%
- Education$1170%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 77 | $15,216 |
| Johnson & Johnson | 33 | $14,906 |
| Lilly USA, LLC | 49 | $706 |
| Novo Nordisk | 52 | $702 |
| Amgen | 28 | $620 |
| Sanofi-aventis U.S. LLC | 24 | $497 |
| Corcept Therapeutics | 20 | $480 |
| Abbott | 37 | $462 |
| Medtronic(2 entities) | 11 | $446 |
| Dexcom, Inc. | 14 | $259 |
| Novartis | 13 | $207 |
| Boehringer Ingelheim | 13 | $201 |
| Insulet Corporation | 6 | $190 |
| IBSA Pharma Inc. | 10 | $176 |
| Mannkind Corporation | 7 | $158 |
| Sequel Med Tech, LLC | 1 | $149 |
| AbbVie | 8 | $121 |
| Tandem Diabetes Care, Inc. | 8 | $121 |
| Ascendis Pharma Endocrinology Inc | 1 | $108 |
| Radius Health, Inc. | 5 | $95 |
| Bayer | 5 | $89 |
| Amarin Pharma, Inc. | 6 | $89 |
| Merck | 4 | $69 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Regeneron Healthcare Solutions, Inc. | 3 | $55 |
| Amphastar Pharmaceuticals, Inc. | 3 | $54 |
| BETA Bionics, Inc. | 5 | $51 |
| Recordati_rare_diseases_inc. | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $45 |
| Intuity Medical Inc | 2 | $37 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Companion Medical, Inc. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Pfizer | 1 | $13 |
| Clarus Therapeutics Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$36,533 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 988 | $1,608,604 |
| MounjaroTirzepatide | 357 | $546,151 |
| JardianceEmpagliflozin | 415 | $490,108 |
| TrulicityDulaglutide | 257 | $388,901 |
| FarxigaDapagliflozin Propanediol | 351 | $335,303 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 219 | $287,981 |
| Xigduo XrDapaglifloz Propaned/Metformin | 196 | $224,579 |
| Tresiba Flextouch U-200Insulin Degludec | 134 | $129,992 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 62 | $69,789 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $61,972 |
| Humalog Kwikpen U-100Insulin Lispro | 151 | $55,711 |
| Tresiba Flextouch U-100Insulin Degludec | 94 | $53,365 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $52,970 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 60 | $50,164 |
| Novolog FlexpenInsulin Aspart | 159 | $43,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $702 | $1,642,6131,050 claims |
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog | $706 | $969,664669 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $201 | $827,232675 claims |
| AstraZenecaFarxiga | $15,216 | $335,303351 claims |
| MerckJanuvia, Janumet Xr | $69 | $50,04448 claims |
| AbbVieSynthroid | $121 | $13,164166 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $497 | $12,57915 claims |
| Johnson & JohnsonInvokana | $14,906 | $12,53011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Peters
- Ranjani RamanathanSaint Peters$5K
- Ralph DudaSpringfield$3M
- Thomas NickolasSaint Louis$945K
- Anne GoldbergSaint Louis$830K
- Janet McGillSaint Louis$828K
- Christopher CaseJefferson City$692K
- Gregory LedgerSpringfield$690K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Julie SilversteinSaint Louis$536K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.